for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion



The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

Official Title

A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis


UC is a chronic disease of the large intestine, in which the lining of the colon becomes inflamed and develops ulcers. Guselkumab is a fully human immunoglobulin G1 lambda monoclonal antibody (mAb) that binds to human interleukin (IL)-23 with high affinity. The study is designed to answer scientific questions pertaining to the efficacy and safety of guselkumab in the treatment of moderately to severely active UC. Overall, the study will evaluate guselkumab treatment through at least 64 weeks. Efficacy, safety, pharmacokinetics (PK), immunogenicity, and biomarkers will be assessed at specified time points.


Ulcerative Colitis Colitis Colitis, Ulcerative Ulcer Antibodies, Monoclonal Guselkumab Induction Study 1: Guselkumab Dose 1 Induction Study 1: Guselkumab Dose 2 Induction Study 1: Guselkumab Dose 3 Induction Study 2: Guselkumab IV


You can join if…

Open to people ages 18 years and up

  • Documented diagnosis of ulcerative colitis (UC)
  • Moderately to severely active UC, defined by modified Mayo score
  • Demonstrated inadequate response or intolerance to medical therapies specified in the protocol
  • Screening laboratory test results within the parameters specified in the protocol

You CAN'T join if...

  • Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, or Crohn's disease or clinical findings suggestive of Crohn's disease
  • UC limited to the rectum only or to less than (<) 20 centimeter (cm) of the colon
  • Presence of a stoma
  • Presence or history of a fistula
  • Receiving prohibited medications and/or treatment


  • UC San Diego
    La Jolla California 92093 United States
  • Om Research LLC
    Lancaster California 93534 United States


currently not accepting new patients, but might later
Start Date
Completion Date
Janssen Research & Development, LLC
To learn how to participate in this trial please click here.
Phase 2/3
Study Type
Last Updated